Manveen Duggal, MD
Endocrinology, Diabetes & Metabolism · Dover, DENPI 1538102686
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.1%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Medtronic at 41.8% of the total. Reporting peaked in 2024 at $1,041 and has fallen 80.1% since, to $207 in 2025.
Across 46 payments — averaging $41.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$794
- Amgen$386
- Abbott$234
- Kyowa Kirin, Inc.$126
- Sanofi-aventis U.S. LLC$104
- Lilly USA, LLC$88
- plus $169 from 8 others
What the payments were for
- Consulting fees$1759%
- Travel & lodging$61432%
- Food & beverage$1,04855%
- Education$643%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 7 | $794 |
| Amgen(2 entities) | 4 | $386 |
| Abbott | 12 | $234 |
| Kyowa Kirin, Inc. | 1 | $126 |
| Sanofi-aventis U.S. LLC | 7 | $104 |
| Lilly USA, LLC | 5 | $88 |
| Novo Nordisk | 3 | $65 |
| Bayer | 1 | $20 |
| AstraZeneca | 1 | $16 |
| Tandem Diabetes Care, Inc. | 1 | $14 |
| Insulet Corporation | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$572
- Prolia$175
- TEPEZZA$145
- CRYSVITA$126
How this compares
$1,900 in reported general payments places this provider in the 60th percentile of 30 endocrinology, diabetes & metabolism providers in Delaware.
See all endocrinology, diabetes & metabolism providers in Delaware →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 288 | $591,564 |
| JardianceEmpagliflozin | 225 | $284,460 |
| TrulicityDulaglutide | 171 | $269,105 |
| MounjaroTirzepatide | 118 | $223,063 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 53 | $97,986 |
| FarxigaDapagliflozin Propanediol | 53 | $51,753 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 31 | $41,950 |
| RybelsusSemaglutide | 18 | $36,051 |
| Tresiba Flextouch U-100Insulin Degludec | 68 | $31,641 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 103 | $26,807 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 13 | $25,464 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 19 | $24,001 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 177 | $23,550 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 39 | $22,119 |
| Novolog FlexpenInsulin Aspart | 45 | $20,396 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $65 | $632,332318 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Lyumjev | $88 | $508,612301 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $14 | $326,410256 claims |
| AstraZenecaFarxiga | $16 | $51,75353 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 30 endocrinology, diabetes & metabolism providers in Delaware.
Other endocrinology, diabetes & metabolism in Dover
- Chitra ChoudharyDover$5K
- Wai Wai LinDover$762
- Hira ShakeelDover$240
- Hajira AmirDover$187
- Hasitha VemulaDover$96
- Ripudaman HundalNewark$370K
- Nira MadisiMilford$23K
- Francisco PadillaSeaford$22K
- Reetu SinghLewes$9K
- Joanna KhatibMillsboro$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.